Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity BLOOD ADV
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study LANCET ONCOL
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results LEUKEMIA LYMPHOMA
Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia GENE CHROMOSOME CANC
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation BRIT J HAEMATOL
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies Front Oncol